ArticleDrug design, development and therapy2025
Renal Function and Hemoglobin Independently Predict Levetiracetam Exposure in Epilepsy Patients: A Multifactorial Regression Study.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Toward adaptive therapeutic timing: integration of mechanistic pharmacology and artificial intelligence in precision dosing.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the key factors influencing the plasma concentration of levetiracetam (LEV) in patients with epilepsy and to establish a predictive model for LEV steady-state trough concentration. Patients and Methods: Clinical data from 130 epilepsy patients (175 steady-state trough concentration blood samples) were retrospectively collected at a single center. Univariate analysis and multiple linear regression modeling were employed to systematically quantify the independent effects of demographic characteristics, biochemical indicators, and concomitant medications on the LEV C/D. The robustness of the model was validated using the Bootstrap method (1000 resamples). Results: Creatinine clearance rate (Ccr) emerged as the strongest independent predictor (unstandardized β = -0.168, Conclusion: Routine clinical indicators Ccr and HGB are core influencing factors of LEV exposure. This model quantifies their independent effects on LEV steady-state trough concentration, providing novel insights into the interindividual variability of LEV pharmacokinetics and offering a potential tool for aiding individualized dosing strategies, especially in resource-limited settings where therapeutic drug monitoring is not readily available. However, its generalizability still needs to be demonstrated through subsequent external validation and prospective multicenter studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.